Login
$BOLT
$5.80 -$0.28 (4.61%) Live

Company Executives

Officer Age 2025 pay Source
William P. Quinn Also a director
President, Chief Executive Officer, Chief Financial Officer, Secretary and Director
55 $4,558,368
Grant Yonehiro
Chief Operating Officer and Chief Business Officer
62 $4,007,443
Sheila Gujrathi Also a director
Chief Strategy Officer
Title from the Form 8-K dated Oct 23, 2026
Not stated Not reported
Sarah Nemec
Senior VP, Finance and PAO
Title from the Form 4 dated Sep 16, 2026
Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 28, 2026 · updated by the 8-K of Oct 23, 2026

Directors
7
serving now
Independent
4 of 6
stated in the proxy; 1 not stated
Average tenure
4.0 years
from year joined
CEO also chairs the board
No
Brian O’Callaghan
Director Age On board Independent Committees Other public boards 2025 pay Source
Brian O’Callaghan
56 2021
5 years
Independent
Compensation Committee · Chair
Indaptus Therapeutics, Inc. $448,937
William P. Quinn
55 2024
2 years
Not independent None stated None stated Paid as CEO
Jakob Dupont, M.D.
61 2024
2 years
Not independent None stated Pyxis Oncology, Inc., Imugene Limited $191,841
Kathleen LaPorte
64 2020
6 years
Independent
Audit Committee · Chair
89bio, CERo Therapeutics Holdings, Inc., Q32 Bio, Precipio Diagnostics $600,249
Nicole Onetto, M.D.
73 2021
5 years
Independent
Nominating and Corporate Governance Committee
Basilea Pharmaceutica AG $310,700
Laura Berner
51 2022
4 years
Independent
Nominating and Corporate Governance Committee · Chair
None stated $173,672
Sheila Gujrathi Joined Oct 23, 2026
- - - - - -

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

4 disclosed in the proxy filed Apr 28, 2026
Dr. Engleman
member of our Board until May 2024; professor at Stanford; co-inventor of patents licensed from Stanford
$91,800
2024

Payments to Stanford under license agreement for annual license fees and patent expense reimbursement

With Stanford University Open in proxy
Dr. Engleman
member of our Board until May 2024; professor at Stanford; co-inventor of patents licensed from Stanford
$62,200
2025

Payments to Stanford under license agreement for annual license fees and patent expense reimbursement

With Stanford University Open in proxy
Dr. Engleman
member of our Board until May 2024; professor at Stanford; co-inventor of patents licensed from Stanford
Amount not stated

As co-inventor, Dr. Engleman is entitled to a share of royalties paid to Stanford under the license agreements; no royalty payments have been made to date

With Stanford University Open in proxy
Dr. Jakob Dupont
Not stated in this section
Amount not stated
2025

Consulting agreement to provide services as a Senior Clinical Advisor; terminated February 2026

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support